A phase III Randomised Controlled Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse.

Trial Profile

A phase III Randomised Controlled Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SORCE
  • Most Recent Events

    • 12 Nov 2017 Results (n=233) assessing survival benefits in subgroup of patients in SORCE trial, published in the Annals of Oncology.
    • 12 Sep 2017 Results of prediction of survival rates, times and benefits by medical oncologists at baseline (n=176) presented at the 42nd European Society for Medical Oncology Congress
    • 01 Feb 2014 Interim results of the surgical procedure performed prior to sorafenib presented at the 2014 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top